Compare SNCY & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNCY | FTRE |
|---|---|---|
| Founded | 1982 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 867.0M | 1.3B |
| IPO Year | 2021 | 2023 |
| Metric | SNCY | FTRE |
|---|---|---|
| Price | $16.17 | $15.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $19.50 | $14.06 |
| AVG Volume (30 Days) | 666.7K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | $1,126,769,000.00 | ★ $2,723,400,000.00 |
| Revenue This Year | $12.27 | N/A |
| Revenue Next Year | $7.51 | $3.09 |
| P/E Ratio | $37.60 | ★ N/A |
| Revenue Growth | ★ 4.74 | 1.00 |
| 52 Week Low | $10.14 | $3.97 |
| 52 Week High | $22.29 | $18.67 |
| Indicator | SNCY | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 45.66 | 69.44 |
| Support Level | $15.36 | $9.01 |
| Resistance Level | $17.93 | $16.20 |
| Average True Range (ATR) | 0.65 | 0.72 |
| MACD | 0.05 | -0.05 |
| Stochastic Oscillator | 49.16 | 87.01 |
Sun Country Airlines Holdings Inc operates low-cost air carriers. The business has two operating segments: Passenger and Cargo. The passenger segment has two internal passenger groups Scheduled service and Charter. The Cargo segment provides air cargo services. The majority of the revenue is from the passenger segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.